Science & Tech · Space · 7 hrs ago
Saudi Arabia sends biological samples to the ISS for disease research
Saudi Arabia has sent the Middle East’s first biological samples of their kind to space as part of the BioGravity-1 mission.
The samples travelled aboard SpaceX CRS-35 to the International Space Station, with work led by the Saudi Space Agency and King Abdullah University of Science and Technology.
The first mission uses samples from healthy donors to create a baseline for later research.
Researchers will use microgravity, the near-weightless conditions in orbit, to study cell changes associated with aging and neurodegenerative diseases.
The program aims to improve understanding of Alzheimer’s disease and multiple sclerosis, but this mission does not test treatments on patients.
The planned second mission will study patient-derived models, and the third will examine treatment responses and possible drug targets.
Those later missions will build on the baseline from this first phase and continue the program’s research in space.
Saudi Arabia sent biological samples to the International Space Station on the BioGravity-1 mission aboard SpaceX CRS-35.
The mission is the first phase of a three-mission research program into Alzheimer’s disease and multiple sclerosis.
The first phase sends reference samples from healthy donors to establish a baseline for later research.
KAUST developed two experiments, SSA-1 and SSA-2, to study cellular changes in microgravity.
The program involves the Saudi Space Agency, KAUST, the National Stem Cell Foundation and Axiom Space, with NASA support.
- Who
- The Saudi Space Agency and King Abdullah University of Science and Technology sent the samples.
- What
- The BioGravity-1 mission carried biological samples to the International Space Station for disease research.
- When
- The article was published on October 14, 2026; the launch date is not stated.
- Where
- The samples were sent to the International Space Station.
- Why
- Researchers aim to study cellular changes associated with aging and neurodegenerative diseases and establish a baseline for later research.
This story does not have two clearly opposing sides.
Healthy-donor reference samples were sent to establish a scientific baseline for later phases.
The program plans to study models derived from patients with Alzheimer’s disease and multiple sclerosis.
The program plans to focus on therapeutic responses and explore potential drug targets in microgravity.
- Mission
- BioGravity-1 aboard SpaceX CRS-35
- Destination
- International Space Station
- Experiments
- SSA-1 and SSA-2
- Research program
- Three consecutive missions
- Research partners
- Saudi Space Agency, KAUST, National Stem Cell Foundation and Axiom Space
What people are saying
The launch of these samples is an important scientific step toward harnessing the space environment to serve human health, and reflects the growth and readiness of national capabilities to take part in advanced research.
I am especially excited about this mission, as the NSCF team will test the 'Brain Organoid Village' concept in microgravity for the first time.